Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines

Susan O'Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Javier Pinilla-Ibarz, Vishnu V.B. Reddy, Neil P. Shah, B. Douglas Smith, David S. SnyderMeir Wetzler, Kristina Gregory, Hema Sundar

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations

Abstract

The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).

Original languageEnglish (US)
Pages (from-to)1327-1340
Number of pages14
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2013

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this